The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …

Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …

Owing to genetic alterations and overexpression, the dysregulation of protein kinases plays
a significant role in the pathogenesis of many autoimmune and neoplastic disorders and …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

Simple Summary Protein phosphorylation is a key regulatory mechanism that controls a
wide variety of cellular responses. This process is catalysed by the members of the protein …

Kinase inhibitor research is a comparatively recent branch of medicinal chemistry and
pharmacology and the first small‐molecule kinase inhibitor, imatinib, was approved for …

Accumulating evidence suggests that the non-receptor tyrosine kinase c-Abl plays an
important role in the progression of Parkinson's disease (PD) and c-Abl inhibition could be …

Dasatinib and radotinib are oral BCR-ABL tyrosine kinase inhibitors that were developed as
drugs for the treatment of chronic myeloid leukemia. We report here that the c-KIT (CD117) …

Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI)
approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly …